首页> 美国卫生研究院文献>Oncotarget >A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells
【2h】

A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells

机译:缺乏外显子2的新型RON剪接变体通过大肠癌细胞中的PTEN磷酸化激活PI3K / AKT途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abnormal expression of the Recepteur d'Origine Nantais (RON) receptor tyrosine kinase is accompanied by the generation of multiple splice or truncated variants, which mediate many critical cellular functions that contribute to tumor progression and metastasis. Here, we report a new RON splice variant in the human colorectal cancer (CRC) cell line HT29. This variant is a 165 kda protein generated by alternative pre-mRNA splicing that eliminates exon 2, causing an in-frame deletion of 63 amino acids in the extracellular domain of the RON β chain. The deleted transcript was a single chain expressed in the intracellular compartment. Although it lacked tyrosine phosphorylation activity, the RONΔ165E2 variant could phosphorylate phosphatase and tensin homolog (PTEN), thereby activating the PI3K/AKT pathway. In addition, in vitro and in vivo experiments showed that the RONΔ165E2 promoted cell migration and tumor growth. Finally, in an investigation of 67 clinical CRC samples, the variant was highly expressed in about 58% of the samples, and was positively correlated with the invasive depth of the tumor (P < 0.05). These results demonstrate that the novel RONΔ165E2 variant promoted tumor progression while activating the PI3K/AKT pathway via PTEN phosphorylation.
机译:d'Origine d'Origine Nantais(RON)受体酪氨酸激酶的异常表达伴随着多个剪接或截短的变异体的产生,这些变异体介导了许多关键的细胞功能,这些功能都有助于肿瘤的发展和转移。在这里,我们报告人类结直肠癌(CRC)细胞系HT29中的新RON剪接变体。该变体是通过消除前外显子2的替代性前mRNA剪接产生的165 kda蛋白,导致RONβ链胞外域中的63个氨基酸在框内缺失。缺失的转录物是在细胞内区室中表达的单链。 RONΔ165 E2 变体虽然缺乏酪氨酸磷酸化活性,但它可以磷酸化磷酸酶和张力蛋白同源物(PTEN),从而激活PI3K / AKT途径。此外,体外和体内实验表明,RONΔ165 E2 促进细胞迁移和肿瘤生长。最后,在对67个临床CRC样本的调查中,该变异体在约58%的样本中高度表达,并且与肿瘤的浸润深度呈正相关(P <0.05)。这些结果表明,新型RONΔ165 E2 变异体通过PTEN磷酸化激活PI3K / AKT途径,同时促进了肿瘤的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号